Navigation Links
Sosei Announces the Out-licensing of RS(+) Mefloquine to Treague Ltd for the Treatment and Prophylaxis of Malaria
Date:11/25/2008

TOKYO and CAMBRIDGE, England, November 26 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announced that it has out-licensed its IP and Know How relating to the RS(+) isomer of mefloquine to Treague Ltd. ("Treague"), a Cambridge, UK based pharma company, for the treatment and prophylaxis of malaria.

Mefloquine is a highly efficacious anti-malarial drug that is approved in its racemic form for both treatment (in combination with artesunate) and prophylaxis (as monotherapy) of malaria. Though its efficacy and long half-life make racemic mefloquine a particularly attractive anti-malarial drug, its clinical utility has been compromised by CNS side effects. However, it is hypothesised, based on the stereoselective nature of mefloquine's receptor binding that RS(+) mefloquine has the potential for substantially reduced CNS side effect liability. Treague is collaborating with Medicines for Malaria Venture (MMV), a Geneva-based not-for-profit organization dedicated to reducing the burden of malaria, to develop RS(+) mefloquine for the treatment of malaria in malaria endemic countries. In addition, Treague plans to develop RS(+) mefloquine for the prophylaxis of malaria for commercial sale.

Based on its cytokine modulatory activity, Sosei were developing RS(+) mefloquine as AD 452 for the treatment of rheumatoid arthritis. However, despite an excellent safety profile, clinical studies failed to demonstrate sufficient efficacy in this indication and the AD 452 programme was terminated in 2006.

"We are delighted to contribute to the development of a potentially safer and better tolerated anti-malarial," said Shinichi Tamura, CEO of Sosei.

Dr Robert Tansley, Treague's Development & Medical Director said, "By building on the pre-clinical and clinical work conducted by Sosei, we have the opportunity to rapidly develop an
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R))
2. Sosei Announces Outcome of Strategy Review
3. Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome
4. Genoptix Announces Participation at the Twentieth Annual Piper Jaffray Healthcare Conference
5. Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
6. Terumo Heart Announces Appointment of William Pinon to Chief Executive Officer and President
7. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
8. Johnson & Johnson Announces Definitive Agreement to Acquire Omrix
9. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
10. CorVel Announces MSA Agent Services
11. Health Robotics Announces $60M Investment by Devon International Group and ITOCHU Inc. in the CytoCare(TM) and i.v.Station(TM PENDING) Robots
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 ... enterprise, announced today that rare disease expert John ... president, research. Dr. McKew brings more than two decades ... at the National Institutes of Health, Wyeth Research and ... McKew will lead aTyr,s efforts to expand and translate ...
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... 20, 2014 PureTech , a science ... healthcare problems, announced today the closing of a ... from Invesco Perpetual, a $120 Billion group of ... PureTech,s existing pipeline forward and to advance new ... scientific creativity to really go for the big ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The Latin ... the market in Latin America with analysis and forecast ... in 2013, and is expected to reach $2,366.8 million ... to 2018. , Browse through the TOC of the ... idea of the in-depth analysis provided. It also provides ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3
... Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the ... ) focused on bringing the life saving potential ... today that Matthew Schissler, founder and CEO, in an ... is very close to becoming cash flow positive.The complete ...
... Feb. 5 Micromet, Inc. (Nasdaq: MITI ), today announced ... BIO CEO and Investor Conference at the Waldorf-Astoria in New York City ... be available on the company,s website at www.micromet-inc.com ., ... Date: Tuesday, February 10, 2009, ...
... Nutrition 21, Inc. (Nasdaq: NXXI ), ... Iceland Health(R), Chromax(R) and Diabetes Essentials(R) brands that help ... memory and reduce chronic joint pain, today announced financial ... of fiscal year 2009.For the quarter the Company reported ...
Cached Biology Technology:In Analyst Interview, Cord Blood America Says Stem Cells Now Front and Center for Researchers and Investors 2Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009 2Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009 3Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009 4Nutrition 21 Announces Second Consecutive Profitable Quarter in Q2 Fiscal 2009 2Nutrition 21 Announces Second Consecutive Profitable Quarter in Q2 Fiscal 2009 3Nutrition 21 Announces Second Consecutive Profitable Quarter in Q2 Fiscal 2009 4Nutrition 21 Announces Second Consecutive Profitable Quarter in Q2 Fiscal 2009 5Nutrition 21 Announces Second Consecutive Profitable Quarter in Q2 Fiscal 2009 6Nutrition 21 Announces Second Consecutive Profitable Quarter in Q2 Fiscal 2009 7
(Date:10/16/2014)... monocultures can be cultivated efficiently, they are anything ... caused by monoculture cultivation is becoming increasingly evident. ... crop form and are regarded as the sole ... – quite wrongfully, finds Bernhard Schmid, an ecology ... a novel form of agriculture and forestry. After ...
(Date:10/15/2014)... pandemic risk from strains of influenza virus increases with ... to become complacent that the most substantial threats have ... Influenza pandemics arise when a new virus strain – ... – spreads in the human population. There have been ... worst of which – the 1918 Spanish Flu – ...
(Date:10/15/2014)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... growing mobile commerce market releases photos and video of the recent ... October 13 th . Gino Pereira , ... angel investor Mr. Chad A. Verdi rang the bell.  ... his investors and employees "for their work and dedication in bringing ...
Breaking Biology News(10 mins):Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3
... developed a new method for delivering molecules into single, ... The technique could find applications in drug delivery, cell ... a technique used to deliver molecules into cells through ... by exposing them to electric pulses is an ...
... uphill battle? Try staying fit in space, where living quarters ... That,s the challenge a group of Michigan State University researchers ... NASA. Their goal is to keep astronauts motivated to exercise ... best exercise regimen there is, but if you can,t get ...
... Philips Electronics (NYSE: PHG, AEX: PHIA) today announced that CX50 ... Live 3D TEE, now offers 2-D Intracardiac Echo (ICE) capability. ... will be shown in Paris at ... Cardiovascular Inventions (EAPCI), May 21-24. Since its launch ...
Cached Biology News:Single-cell transfection tool enables added control for biological studies 2Fueling fitness on the final frontier 2Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2
Best pricing for 100mg-1.0g scales. Phosphopeptides are our specialty....
... 2D is an automated, two-dimensional fractionation system ... Part of Beckman Coulters ProteomeLab family ... in just hours. The system effectively ... cell lysates, addressing a key challenge in ...
... The Rapid-Screen cDNA Library Panels were designed ... three sets of PCRs to identify the ... is performed in a 96-well "Master Plate," ... 5,000 clones. Having identified the positive well(s) ...
... HORIBA Jobin Yvons Protein 295 ex ... a protein sample in only a few ... the amino acids tyrosine and tryptophan, the ... powerful NanoLED-17, a pulsed diode emitting 295 ...
Biology Products: